Key Highlights

  • Shares are down 12.76% in pre-market trading to $19.63, after closing down 2.13% at $22.50 the prior session.
  • The decline is part of a broad selloff across neuromuscular and gene therapy stocks following Novartis's disclosure that its del-desiran drug failed a Phase 3 trial in myotonic dystrophy type 1, a related but distinct neuromuscular disease.
  • Sarepta's own announcement today was unrelated to any trial data, naming 25 recipients of its Route 79 Duchenne Scholarship Program for the 2026-2027 academic year.
  • The company holds a Leadership position in Duchenne muscular dystrophy, with a commercial portfolio including the exon-skipping Franchise and the gene therapy Elevidys.

This Gene Therapy Stock Is Falling Today Amid Sector Contagion

Shares of this NASDAQ-listed commercial-stage biotechnology company are down 12.76% in pre-market trading to $19.63, falling sharply despite the company's own news today being entirely unrelated to clinical trial data. The decline reflects broad contagion across neuromuscular disease and gene therapy stocks after a competitor's Phase 3 trial failure in a related, though distinct, disease category raised fresh questions about the durability and risk profile of the entire treatment landscape.

Sarepta Therapeutics (NASDAQ:SRPT) is a Cambridge, Massachusetts-based commercial-stage biotechnology company focused on discovering and developing precision genetic medicines, including RNA-targeted therapeutics and gene therapies, for rare diseases, with particular depth in Duchenne muscular dystrophy and limb-girdle muscular dystrophies. Its commercial portfolio includes the PMO exon-skipping franchise, comprising Exondys 51, Vyondys 53, and Amondys 45, and the gene therapy Elevidys, alongside an active pipeline supported by collaborations with partners including Roche.

Sector Selloff Traces Back to a Related Disease Category's Trial Failure

The broader selloff traces back to Novartis (NYSE:NVS), which disclosed that its Phase 3 HARBOR trial testing del-desiran in patients with myotonic dystrophy type 1 failed to show that the drug significantly improved patients' ability to open their hands faster than a placebo. The failure marked Novartis's third drug trial setback in a single week, following a separate cardiovascular trial miss and a paused cell therapy program, and has triggered a wave of risk reassessment across neuromuscular and rare disease biotech names more broadly, even those, like Sarepta, focused on a different underlying disease.

Sarepta's actual news today, the naming of 25 scholarship recipients through its Route 79 program supporting students living with Duchenne and their siblings, has no bearing on the company's clinical or commercial outlook. The stock's decline appears to be a case of sympathy selling within the neuromuscular disease space rather than a reaction to anything specific to Sarepta's own Duchenne muscular dystrophy programs or Elevidys sales trajectory.

Where Things Stand

Today's decline illustrates how closely correlated neuromuscular and rare disease gene therapy stocks can trade during periods of sector-wide risk reassessment, even when the underlying diseases and drug mechanisms differ substantially between companies. Myotonic dystrophy type 1 and Duchenne muscular dystrophy are distinct conditions with different genetic causes and treatment approaches, meaning Novartis's del-desiran failure carries limited direct read-through to Sarepta's own pipeline or its approved Elevidys gene therapy. Sarepta's exon-skipping franchise and Elevidys have their own distinct commercial trajectories and regulatory history, separate from any of the Assets involved in Novartis's recent setbacks.

Investors will likely need company-specific data or commercial updates from Sarepta itself to determine whether today's pullback represents an overreaction or a more durable repricing of risk across the sector. Given that Sarepta's actual news today was a philanthropic scholarship announcement rather than any clinical or regulatory update, the size of today's decline suggests sentiment across the neuromuscular and gene therapy space is currently more fragile than company-specific fundamentals alone would justify.